These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 15949585)

  • 21. Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum.
    Kopreski MS; Benko FA; Gocke CD
    Ann N Y Acad Sci; 2001 Sep; 945():172-8. PubMed ID: 11708475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of free RNA in serum and bronchial lavage: a new diagnostic tool in lung cancer detection?
    Schmidt B; Engel E; Carstensen T; Weickmann S; John M; Witt C; Fleischhacker M
    Lung Cancer; 2005 Apr; 48(1):145-7. PubMed ID: 15777983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA methylation analysis: a powerful new tool for lung cancer diagnosis.
    Tsou JA; Hagen JA; Carpenter CL; Laird-Offringa IA
    Oncogene; 2002 Aug; 21(35):5450-61. PubMed ID: 12154407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
    Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
    Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Free circulating nucleic acids in plasma and serum (CNAPS) -- Useful for the detection of lung cancer patients?
    Fleischhacker M; Schmidt B
    Cancer Biomark; 2010; 6(3-4):211-9. PubMed ID: 20660966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular detection of low-level disease in patients with cancer.
    Burchill SA; Selby PJ
    J Pathol; 2000 Jan; 190(1):6-14. PubMed ID: 10640986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microsatellite analysis of induced sputum DNA in patients with lung cancer in heavy smokers and in healthy subjects.
    Castagnaro A; Marangio E; Verduri A; Chetta A; D'Ippolito R; Del Donno M; Olivieri D; Di Cola G
    Exp Lung Res; 2007 Aug; 33(6):289-301. PubMed ID: 17694439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating free tumor DNA and colorectal cancer.
    Lecomte T; Ceze N; Dorval E; Laurent-Puig P
    Gastroenterol Clin Biol; 2010 Dec; 34(12):662-81. PubMed ID: 20832215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Aberrant promoter methylation as biomarker for molecular cytological diagnosis of lung cancer].
    Grote HJ
    Verh Dtsch Ges Pathol; 2006; 90():216-26. PubMed ID: 17867600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating nucleic acids in plasma and serum: past, present and future.
    Taback B; Hoon DS
    Curr Opin Mol Ther; 2004 Jun; 6(3):273-8. PubMed ID: 15264429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Free circulating DNA as possible tumour marker in colorectal cancer.
    Boni L; Cassinotti E; Canziani M; Dionigi G; Rovera F; Dionigi R
    Surg Oncol; 2007 Dec; 16 Suppl 1():S29-31. PubMed ID: 18024018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating methylated DNA.
    Herman JG
    Ann N Y Acad Sci; 2004 Jun; 1022():33-9. PubMed ID: 15251936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
    Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M
    Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.
    Modlin IM; Gustafsson BI; Drozdov I; Nadler B; Pfragner R; Kidd M
    Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alport syndrome. Molecular genetic aspects.
    Hertz JM
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.
    Hosny G; Farahat N; Hainaut P
    Cancer Lett; 2009 Mar; 275(2):234-9. PubMed ID: 19046801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantification of circulating DNA in the plasma and serum of cancer patients.
    Taback B; O'Day SJ; Hoon DS
    Ann N Y Acad Sci; 2004 Jun; 1022():17-24. PubMed ID: 15251934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR.
    Ntoulia M; Stathopoulou A; Ignatiadis M; Malamos N; Mavroudis D; Georgoulias V; Lianidou ES
    Clin Biochem; 2006 Sep; 39(9):879-87. PubMed ID: 16925986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.